Yuriev and Flynn win RACI awards

Two MIPS researchers have been recognised at the 2019 Royal Australia Chemical Institute (RACI) Awards.

Dr Elizabeth Yuriev has been named Educator of the Year and Associate Professor Bernie Flynn has won the Applied Research Award.

The RACI Educator of the Year Award provides recognition to developing teachers, from tutors to senior lecturers, teaching in undergraduate or postgraduate university courses.

MU

Dr Yuriev’s research group at Monash University has developed a workflow to help chemistry students establish problem-solving skills. The tool, called ‘Goldilocks Help’, is designed to guide students out of dead ends and false starts. When implemented, it has increased the students’ ability to use problem-solving strategies, as well as confidence in their ability to do so.

The Award comes hot on the heels of Dr Yuriev’s receipt of one of four Monash Education Academy grants through the Inter-Faculty Transformation Grant (IFTG) scheme.

The scheme champions cross-disciplinary team projects that have the capacity to effect new and sustainable change to educational practice across more than one Faculty at the University.

Dr Yuriev's project is titled ‘STEMMing Effective Study Strategies’. The project is exploring the creation of a research-informed toolkit of learning activities and guidelines that educators can use to integrate study skills into STEM teaching and learning.

The RACI Applied Research Award is given to a member of the RACI who has contributed significantly towards the development of, or innovation through, applied research or in industrial fields.

Associate Professor Flynn was recognised for his work, performed at the interface of chemistry and biology, in finding new treatments for disease.

Using small molecules as probes, Associate Professor Flynn works to find promising biological sites for therapeutics and to obtain clues about the chemistry needed to target such sites. Together with co-workers, he has produced many promising drug leads for the treatment of cancer, liver disease, multiple sclerosis and anxiety. Some of these drugs have proceeded to clinical trials.

Currently, his team at the Monash Institute of Pharmaceutical Sciences is working on treating chronic kidney disease, liver disease and heart failure. They are targeting enzymes involved in the biological processes that lead to organ failure in the course of these conditions.

He is also the co-Director of the Australian Translational Medicinal Chemistry Facility and Founder and CEO of Cincera Therapeutics.

Contact: Divya Krishnan

Phone:

Email: divya.krishnan@monash.edu